ALL - 642
The emerging role of Venetoclax in high risk newly diagnosed patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)
Maher Salamoon
Poster Presenter: Maher Salamoon
1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors
ePostersLive by SciGen Technologies S.A. All rights reserved.
SOHO 2026 Annual Meeting
September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas
Authors
Showing 10 results for author "Maher Salamoon".
ALL - 840
The Role of Blinatumomab in CD19-Positive Precursor B-Cell Acute Lymphoblastic Leukemia Philadelphia-Negative Disease: A 3-Year Update on Progression-Free Survival
Maher Salamoon
Poster Presenter: Maher Salamoon
AML - 639
Preinduction With Azacitidine and Venetoclax in Newly Diagnosed Patients With Acute Myelogenous Leukemia: 3-Year Survival Update of a Comparative Study
Maher Salamoon
Poster Presenter: Maher Salamoon
AML - 643
Real-world practice with generic venetoclax and generic Azacitidine in Acute Myelogenous Leukemia (AML) with different risk groups
Maher Salamoon
Poster Presenter: Maher Salamoon
AML - 843
All-Oral Treatment in Patients Older Than 65 Years With Newly Diagnosed Acute Myelogenous Leukemia: Progression-Free Survival and Toxicity
Maher Salamoon
Poster Presenter: Maher Salamoon
CLL - 630
Frequency and Factors Predisposing to Pulmonary Infections in Patients With Chronic Lymphocytic Leukemia Treated With Targeted Agents
Maher Salamoon
Poster Presenter: Maher Salamoon
MDS - 635
Treatment of higher risk Myelodysplastic Syndrome HR-MDS with high-dose chemotherapy followed by lenalidomide and azacitidine: a four-year survival update
Maher Salamoon
Poster Presenter: Maher Salamoon
MDS - 644
The best Venetoclax dosing schedule in high-risk Myelodysplastic Syndrome (MDS)
Maher Salamoon
Poster Presenter: Maher Salamoon
MM - 633
Treatment of high-risk smoldering multiple myeloma (HRSMM) with Isatuximab, lenalidomide, oral Cyclophosphamide and Dexamethasone: a survival advantage
Maher Salamoon
Poster Presenter: Maher Salamoon